S&P 500   3,855.36
DOW   30,960.00
QQQ   328.11
S&P 500   3,855.36
DOW   30,960.00
QQQ   328.11
S&P 500   3,855.36
DOW   30,960.00
QQQ   328.11
S&P 500   3,855.36
DOW   30,960.00
QQQ   328.11
Log in
NASDAQ:TLRY

Tilray Competitors

$17.18
-0.84 (-4.66 %)
(As of 01/25/2021 12:00 AM ET)
Add
Compare
Today's Range
$15.60
Now: $17.19
$18.30
50-Day Range
$7.37
MA: $11.40
$20.09
52-Week Range
$2.43
Now: $17.19
$22.61
Volume25.72 million shs
Average Volume40.17 million shs
Market Capitalization$2.29 billion
P/E RatioN/A
Dividend YieldN/A
Beta3.12

Competitors

Tilray (NASDAQ:TLRY) Vs. APHA, CRON, USNA, ACB, HEXO, and SNDL

Should you be buying TLRY stock or one of its competitors? Companies in the industry of "medicinals & botanicals" are considered alternatives and competitors to Tilray, including Aphria (APHA), Cronos Group (CRON), USANA Health Sciences (USNA), Aurora Cannabis (ACB), HEXO (HEXO), and Sundial Growers (SNDL).

Aphria (NASDAQ:APHA) and Tilray (NASDAQ:TLRY) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

Profitability

This table compares Aphria and Tilray's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Aphria-36.10%-2.30%-1.66%
Tilray-242.60%-92.70%-20.70%

Valuation and Earnings

This table compares Aphria and Tilray's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aphria$405.96 million8.83$-63,210,000.00($0.06)-200.17
Tilray$166.98 million13.74$-321,170,000.00($1.69)-10.17

Aphria has higher revenue and earnings than Tilray. Aphria is trading at a lower price-to-earnings ratio than Tilray, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

10.3% of Aphria shares are held by institutional investors. Comparatively, 12.6% of Tilray shares are held by institutional investors. 16.8% of Tilray shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of recent recommendations for Aphria and Tilray, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aphria03602.67
Tilray210101.92

Aphria presently has a consensus target price of $17.00, suggesting a potential upside of 41.55%. Tilray has a consensus target price of $12.2720, suggesting a potential downside of 28.59%. Given Aphria's stronger consensus rating and higher probable upside, equities research analysts clearly believe Aphria is more favorable than Tilray.

Risk and Volatility

Aphria has a beta of 2.67, suggesting that its share price is 167% more volatile than the S&P 500. Comparatively, Tilray has a beta of 3.12, suggesting that its share price is 212% more volatile than the S&P 500.

Summary

Aphria beats Tilray on 9 of the 14 factors compared between the two stocks.

Cronos Group (NASDAQ:CRON) and Tilray (NASDAQ:TLRY) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

Profitability

This table compares Cronos Group and Tilray's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cronos Group266.31%-1.61%-1.41%
Tilray-242.60%-92.70%-20.70%

Valuation and Earnings

This table compares Cronos Group and Tilray's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cronos Group$25.64 million137.51$1.17 billion$0.6714.79
Tilray$166.98 million13.74$-321,170,000.00($1.69)-10.17

Cronos Group has higher earnings, but lower revenue than Tilray. Tilray is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

11.8% of Cronos Group shares are held by institutional investors. Comparatively, 12.6% of Tilray shares are held by institutional investors. 7.9% of Cronos Group shares are held by company insiders. Comparatively, 16.8% of Tilray shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of recent recommendations for Cronos Group and Tilray, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cronos Group24202.00
Tilray210101.92

Cronos Group presently has a consensus target price of $8.1875, suggesting a potential downside of 17.38%. Tilray has a consensus target price of $12.2720, suggesting a potential downside of 28.59%. Given Cronos Group's stronger consensus rating and higher probable upside, equities research analysts clearly believe Cronos Group is more favorable than Tilray.

Risk and Volatility

Cronos Group has a beta of 2.07, suggesting that its share price is 107% more volatile than the S&P 500. Comparatively, Tilray has a beta of 3.12, suggesting that its share price is 212% more volatile than the S&P 500.

Summary

Cronos Group beats Tilray on 10 of the 14 factors compared between the two stocks.

USANA Health Sciences (NYSE:USNA) and Tilray (NASDAQ:TLRY) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

Profitability

This table compares USANA Health Sciences and Tilray's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
USANA Health Sciences10.57%32.91%22.26%
Tilray-242.60%-92.70%-20.70%

Valuation and Earnings

This table compares USANA Health Sciences and Tilray's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
USANA Health Sciences$1.06 billion1.78$100.53 million$4.4120.31
Tilray$166.98 million13.74$-321,170,000.00($1.69)-10.17

USANA Health Sciences has higher revenue and earnings than Tilray. Tilray is trading at a lower price-to-earnings ratio than USANA Health Sciences, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

54.1% of USANA Health Sciences shares are held by institutional investors. Comparatively, 12.6% of Tilray shares are held by institutional investors. 45.4% of USANA Health Sciences shares are held by company insiders. Comparatively, 16.8% of Tilray shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of recent recommendations for USANA Health Sciences and Tilray, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
USANA Health Sciences00203.00
Tilray210101.92

USANA Health Sciences presently has a consensus target price of $107.00, suggesting a potential upside of 19.47%. Tilray has a consensus target price of $12.2720, suggesting a potential downside of 28.59%. Given USANA Health Sciences' stronger consensus rating and higher probable upside, equities research analysts clearly believe USANA Health Sciences is more favorable than Tilray.

Risk and Volatility

USANA Health Sciences has a beta of 0.98, suggesting that its share price is 2% less volatile than the S&P 500. Comparatively, Tilray has a beta of 3.12, suggesting that its share price is 212% more volatile than the S&P 500.

Summary

USANA Health Sciences beats Tilray on 12 of the 14 factors compared between the two stocks.

Aurora Cannabis (NYSE:ACB) and Tilray (NASDAQ:TLRY) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

Risk and Volatility

Aurora Cannabis has a beta of 3.44, suggesting that its share price is 244% more volatile than the S&P 500. Comparatively, Tilray has a beta of 3.12, suggesting that its share price is 212% more volatile than the S&P 500.

Insider and Institutional Ownership

11.9% of Aurora Cannabis shares are held by institutional investors. Comparatively, 12.6% of Tilray shares are held by institutional investors. 16.8% of Tilray shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of recent recommendations for Aurora Cannabis and Tilray, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aurora Cannabis412101.82
Tilray210101.92

Aurora Cannabis presently has a consensus target price of $12.9421, suggesting a potential upside of 27.38%. Tilray has a consensus target price of $12.2720, suggesting a potential downside of 28.59%. Given Aurora Cannabis' higher probable upside, equities research analysts clearly believe Aurora Cannabis is more favorable than Tilray.

Profitability

This table compares Aurora Cannabis and Tilray's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Aurora Cannabis-1,238.94%-16.32%-13.12%
Tilray-242.60%-92.70%-20.70%

Valuation and Earnings

This table compares Aurora Cannabis and Tilray's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aurora Cannabis$207.89 million6.93$-2,468,190,000.00($2.86)-3.55
Tilray$166.98 million13.74$-321,170,000.00($1.69)-10.17

Tilray has lower revenue, but higher earnings than Aurora Cannabis. Tilray is trading at a lower price-to-earnings ratio than Aurora Cannabis, indicating that it is currently the more affordable of the two stocks.

Summary

Tilray beats Aurora Cannabis on 7 of the 13 factors compared between the two stocks.

Tilray (NASDAQ:TLRY) and HEXO (NYSE:HEXO) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, risk, valuation and earnings.

Volatility & Risk

Tilray has a beta of 3.12, suggesting that its stock price is 212% more volatile than the S&P 500. Comparatively, HEXO has a beta of 1.41, suggesting that its stock price is 41% more volatile than the S&P 500.

Institutional and Insider Ownership

12.6% of Tilray shares are held by institutional investors. Comparatively, 35.3% of HEXO shares are held by institutional investors. 16.8% of Tilray shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Tilray and HEXO, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Tilray210101.92
HEXO69101.69

Tilray currently has a consensus target price of $12.2720, indicating a potential downside of 28.59%. HEXO has a consensus target price of $1.15, indicating a potential downside of 81.18%. Given Tilray's stronger consensus rating and higher probable upside, research analysts clearly believe Tilray is more favorable than HEXO.

Profitability

This table compares Tilray and HEXO's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Tilray-242.60%-92.70%-20.70%
HEXO-517.61%-13.15%-10.35%

Valuation and Earnings

This table compares Tilray and HEXO's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tilray$166.98 million13.74$-321,170,000.00($1.69)-10.17
HEXO$60.46 million12.35$-406,370,000.00($0.96)-6.36

Tilray has higher revenue and earnings than HEXO. Tilray is trading at a lower price-to-earnings ratio than HEXO, indicating that it is currently the more affordable of the two stocks.

Summary

Tilray beats HEXO on 8 of the 13 factors compared between the two stocks.

Tilray (NASDAQ:TLRY) and Sundial Growers (NASDAQ:SNDL) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, risk, valuation and earnings.

Volatility & Risk

Tilray has a beta of 3.12, suggesting that its stock price is 212% more volatile than the S&P 500. Comparatively, Sundial Growers has a beta of 7.01, suggesting that its stock price is 601% more volatile than the S&P 500.

Institutional and Insider Ownership

12.6% of Tilray shares are held by institutional investors. Comparatively, 3.3% of Sundial Growers shares are held by institutional investors. 16.8% of Tilray shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Tilray and Sundial Growers, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Tilray210101.92
Sundial Growers13001.75

Tilray currently has a consensus target price of $12.2720, indicating a potential downside of 28.59%. Sundial Growers has a consensus target price of $1.25, indicating a potential upside of 108.51%. Given Sundial Growers' higher probable upside, analysts clearly believe Sundial Growers is more favorable than Tilray.

Profitability

This table compares Tilray and Sundial Growers' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Tilray-242.60%-92.70%-20.70%
Sundial Growers-415.89%-187.67%-72.67%

Valuation and Earnings

This table compares Tilray and Sundial Growers' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tilray$166.98 million13.74$-321,170,000.00($1.69)-10.17
Sundial Growers$75.86 million5.59$-204,570,000.00($3.17)-0.19

Sundial Growers has lower revenue, but higher earnings than Tilray. Tilray is trading at a lower price-to-earnings ratio than Sundial Growers, indicating that it is currently the more affordable of the two stocks.

Summary

Tilray beats Sundial Growers on 10 of the 14 factors compared between the two stocks.


Tilray Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
APHA
Aphria
1.8$12.01-7.6%$3.59 billion$405.96 million-20.36
Cronos Group logo
CRON
Cronos Group
0.7$9.91-7.5%$3.53 billion$25.64 million41.29
USANA Health Sciences logo
USNA
USANA Health Sciences
1.8$89.56-3.2%$1.88 billion$1.06 billion16.59
Aurora Cannabis logo
ACB
Aurora Cannabis
1.5$10.16-4.8%$1.44 billion$207.89 million-0.42Analyst Report
HEXO
HEXO
0.7$6.11-9.5%$746.42 million$60.46 million-1.25
SNDL
Sundial Growers
1.4$0.60-8.3%$423.70 million$75.86 million-0.23
ChromaDex logo
CDXC
ChromaDex
1.3$4.89-0.2%$302.14 million$46.29 million-12.87
MediWound logo
MDWD
MediWound
1.1$5.10-3.5%$138.78 million$31.79 million-12.75
NAII
Natural Alternatives International
0.4$13.23-2.1%$85.68 million$118.88 million165.39Gap Down
HAPP
Happiness Biotech Group
0.6$2.15-8.8%$55.69 million$65.06 million0.00Gap Down
HUGE
FSD Pharma
0.3$2.27-0.4%$43.50 million$190,000.00-0.51
MTEX
Mannatech
1.1$19.10-0.6%$39.88 million$157.73 million5.88
CYAN
Cyanotech
0.9$3.37-3.6%$20.55 million$31.90 million33.70
This page was last updated on 1/26/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.